Biotechnology News and Research

RSS

Protein points to anticancer drug targets

A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the “on-switch cells” used to accelerate cell replication.

20 Sep 2004

Crucell and AIDS Vaccine Initiative have signed an exclusive license agreement to develop an AIDS vaccine

Dutch biotechnology company Crucell and the International AIDS Vaccine Initiative (IAVI) have signed an exclusive license agreement to develop an AIDS vaccine based on Crucell’s AdVac® technology.

20 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

First molecular-scale images of DNA binding to an adenovirus enzyme

The images, which appear on the cover of the October 2004 issue of Molecular and Cellular Proteomics, show how binding to DNA may stimulate the enzyme and are already being used to design new antiviral drugs to block this interaction.

14 Sep 2004

Genetically modified bacterium as remedy for intestinal diseases

Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at Ghent University are joining the fight against chronic intestinal disease with a genetically modified bacterium (Lactococcus lactis).

14 Sep 2004

Statistical method for faster prognosis of Alzheimer’s and Parkinson’s diseases

A large number of diseases − including Alzheimer’s disease, Parkinson’s disease, and mad cow disease − are the result of proteins that erroneously assume the wrong shape, causing them to stick to each other.

13 Sep 2004

Gene therapy holds much promise for treating aggressive human superficial bladder cancer

Gene therapy that causes the bladder to act like a “bioreactor” to produce and secrete the anti-cancer agent interferon-alpha has shown dramatic benefits in preclinical tests, say researchers at The University of Texas M. D. Anderson Cancer Center.

8 Sep 2004

University of Utah gets patent approval relating to methods of rapid nucleic acid amplification

The U.S. Patent and Trademark Office has issued the University of Utah U.S. patent No. U.S. 6,787,338 (the '338 patent) relating to methods of rapid nucleic acid amplification.

8 Sep 2004

MorphoSys obtains license on human cell line technology for use in its antibody research

MorphoSys has announced today a non-exclusive license agreement with Dutch biotechnology company Crucell and DSM Biologics.

8 Sep 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

Sinovac Biotech Ltd. has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with two doses of either SARS vaccine or placebo.

7 Sep 2004

More than 100 million doses of influenza vaccine available this year in the United States

Despite an Aug. 26 announcement that some doses of influenza vaccine to the United States have been delayed, the Centers for Disease Control and Prevention said the effects of the delay will be minimal - and physicians do not need to order more doses.

5 Sep 2004

World needs to commit more resources to treat people infected with HIV

Leaders of the International AIDS Vaccine Initiative (IAVI) have stressed that as the world commits more resources to treat people infected with HIV, it must also intensify efforts to develop a vaccine to prevent new infections and stop the continuing spread of the virus.

2 Sep 2004

Researchers accurately pinpoint the types of lymphoma, Hodgkins or non-Hodgkins

“There are many types and subtypes of lymphoma, some of which are easy to detect, but many that are very difficult to identify,” says Antonio Giordano, M.D., Ph.D., director of the Sbarro Institute at Temple and one of the study’s principal investigators.

1 Sep 2004

Scientists to tackle the most common cause of diarrhoea world-wide with DNA sequencing

Returning holidaymakers may be comforted to know that travellers' diarrhoea could be a thing of the past. Scientists at the University of Birmingham's Medical School are set to sequence the DNA of the bacterium: this will identify causes of illness and point to better cures.

31 Aug 2004

Kiwis reverse heart disease in diabetics

New Zealand biopharmaceutical company Protemix Corporation has announced the discovery of a treatment which appears to reverse heart disease in people suffering from diabetes and may lead to a more effective intervention in a major cause of death worldwide.

30 Aug 2004

Attention deficit/hyperactivity disorder high among Chernobyl children

In an extensive study of children exposed to varying levels of fallout from the 1986 Chernobyl Nuclear Power Plant accident, Israeli researchers have found that Attention Deficit/Hyperactivity Disorder (ADHD) scores are higher among those who were in-utero at the time of the accident -- regardless of their actual level of radiation exposure.

26 Aug 2004

StemCells issued U.S. stem cell patent

StemCells, Inc. has announced that the Company has been issued U.S. patent 6,777,233 for work done at the Company covering composition of matter claims for the human neural stem cell.

23 Aug 2004

Research offers hope for the millions of diabetics worldwide who take insulin injections

University of Toronto researchers have identified individual cells in the adult mouse pancreas capable of generating insulin-producing beta cells.

22 Aug 2004

Existing hepatitis drug could lead to the development of new drugs for the treatment of anthrax

Thanks to new screening tools, and some luck, researchers at the University of Chicago have discovered three unrelated compounds that inhibit the two toxins – edema factor and lethal factor -- that have made anthrax one of the most feared of potential bioterror agents.

21 Aug 2004

Biotechnology News and Research

Protein points to anticancer drug targets

Crucell and AIDS Vaccine Initiative have signed an exclusive license agreement to develop an AIDS vaccine

RNAi enlisted in hunt for prawn vaccines

First molecular-scale images of DNA binding to an adenovirus enzyme

Genetically modified bacterium as remedy for intestinal diseases

Statistical method for faster prognosis of Alzheimer’s and Parkinson’s diseases

Gene therapy holds much promise for treating aggressive human superficial bladder cancer

University of Utah gets patent approval relating to methods of rapid nucleic acid amplification

MorphoSys obtains license on human cell line technology for use in its antibody research

Advances in gene silencing on the agenda

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

More than 100 million doses of influenza vaccine available this year in the United States

World needs to commit more resources to treat people infected with HIV

Researchers accurately pinpoint the types of lymphoma, Hodgkins or non-Hodgkins

Scientists to tackle the most common cause of diarrhoea world-wide with DNA sequencing

Kiwis reverse heart disease in diabetics

Attention deficit/hyperactivity disorder high among Chernobyl children

StemCells issued U.S. stem cell patent

Research offers hope for the millions of diabetics worldwide who take insulin injections

Existing hepatitis drug could lead to the development of new drugs for the treatment of anthrax

Biotechnology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News